Quantitative structure–activity relationship: promising advances in drug discovery platforms
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Quantitative structure-activity relationship (QSAR) modeling is one of the most popular computer-aided tools employed in medicinal chemistry for drug discovery and lead optimization. It is especially powerful in the absence of 3D structures of specific drug targets. QSAR methods have been shown to draw public attention since they were first introduced. AREAS COVERED: In this review, the authors provide a brief discussion of the basic principles of QSAR, model development and model validation. They also highlight the current applications of QSAR in different fields, particularly in virtual screening, rational drug design and multi-target QSAR. Finally, in view of recent controversies, the authors detail the challenges faced by QSAR modeling and the relevant solutions. The aim of this review is to show how QSAR modeling can be applied in novel drug discovery, design and lead optimization. EXPERT OPINION: QSAR should intentionally be used as a powerful tool for fragment-based drug design platforms in the field of drug discovery and design. Although there have been an increasing number of experimentally determined protein structures in recent years, a great number of protein structures cannot be easily obtained (i.e., membrane transport proteins and G-protein coupled receptors). Fragment-based drug discovery, such as QSAR, could be applied further and have a significant role in dealing with these problems. Moreover, along with the development of computer software and hardware, it is believed that QSAR will be increasingly important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection
Kohavi, R. (1995) · Zenodo · doi:10.5281/zenodo.19712698 · Cited by 10,909
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382 · cited 1×
“Public databases [41] are useful for selecting active and inactive components as several hundred thousands of compounds have been tested against different biological targets; these include ChEMBL [42,43] , PubChem [44,45] , ZINC and the Accelrys Available Chemicals Directory.”
Handbook of Molecular Descriptors
Todeschini, R., & Consonni, V. (2000) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527613106 · Cited by 4,107 · cited 1×
“Considering the huge number of descriptors [47], determining a suitable choice of MDs greatly influences the success and performance of any developed QSAR model [48-50].”
BackgroundCramer, R. D., Patterson, D. E., & Bunce, J. D. (1988) · Journal of the American Chemical Society · doi:10.1021/ja00226a005 · Cited by 3,931
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 1×
“However, traditional drug design and development is a complex, costly and laborious process [5-7].”
Backgroundp-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure
Hansch, C., & Fujita, T. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a035 · Cited by 2,313
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
On Outliers and Activity CliffsWhy QSAR Often Disappoints
Maggiora, G. M. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci060117s · Cited by 728
How not to develop a quantitative structure–activity or structure–property relationship (QSAR/QSPR)
Dearden, J. C., Cronin, M. T. D., & Kaiser, K. L. E. (2009) · SAR and QSAR in Environmental Research · doi:10.1080/10629360902949567 · Cited by 468
Why do we need so many chemical similarity search methods?
Sheridan, R. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02411-x · Cited by 412 · cited 1×
“First, bio-activities are explored by molecular fingerprint-based techniques and similarity searches [33-35] .”
Cited by
From machine learning to deep learning: progress in machine intelligence for rational drug discovery
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.010 · Cited by 760
A Review on Applications of Computational Methods in Drug Screening and Design
Lin, X., Li, X., & Lin, X. (2020) · Molecules · doi:10.3390/molecules25061375 · Cited by 718
“In the process of drug discovery, machine intelligence methods have mostly been used in the above-mentioned computational methods over the past few decades [73].”
MethodVatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Use of machine learning approaches for novel drug discovery
Lima, A. N., Philot, E. A., Trossini, G. H. G., Scott, L. P. B., Maltarollo, V. G., & Honorio, K. M. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1146250 · Cited by 254
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
Metadata
- Authors
- Wang, T., Wu, M.-B., Lin, J.-P., & Yang, L.-R.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2015-09-11
- Volume
- 10
- Issue
- 12
- Pages
- 1283-1300
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2141095292
- Cited by
- 124
- References
- 13
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantitative structure–activity relationship: promising advances in drug discovery platforms. https://app.cochat.ai/papers/10.1517/17460441.2015.1083006
- The paper
- Wang, T., Wu, M.-B., Lin, J.-P., & Yang, L.-R. (2015). Quantitative structure–activity relationship: promising advances in drug discovery platforms. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2015.1083006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.